Clinical Trial

Sodium Butyrate and Kluyveromyces Marxianus Supplementation in Inflammatory Bowel Disease

Study acronym: Butymixx
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if a dietary supplement called ButyMixx can help people with ulcerative colitis in remission feel better and keep their intestines less inflamed. ButyMixx contains: * Sodium butyrate, a substance normally produced by our gut microbiota that helps protect the intestinal lining and reduce inflammation. * A "beneficial" yeast (Kluyveromyces marxianus), similar to probiotics, which may support the balance of the intestinal microbiota. It will also learn about the safety of dietary supplement. The main questions it aims to answer are: * Does ButyMixx after 2 months of supplementation * Symptoms improve, * Quality of life improves, * Intestinal inflammation decreases , * The gut microbiota becomes more "balanced" * What medical problems do participants have when taking ButyMixx ? Participants will: * Take 2 sachets of ButyMixx per day for 8 weeks * Before starting and at the end of the 8 weeks: * Provide a stool sample * Complete a quality-of-life questionnaire * Be assessed by a doctor using a symptom score
Trial Details
NCT Number NCT07591012
Lead Sponsor University of Padova
Conditions Ulcerative Colitis (Disorder)
Enrollment 40 participants
Start Date 2026-05-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-15